J Korean Liver Cancer Stud Search


Journal of the Korean Liver Cancer Study 2012;12(1):5-9.
Published online February 28, 2012.
Hepatic Artery Infusion Chemotherapy for Advanced Hepatocellular Carcinoma
Myeong Jun Song, Si Hyun Bae
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
Correspondence:  Si Hyun Bae,
Email: baesh@catholic.ac.kr
Copyright ©2012 by The Korean Liver Cancer Association
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Surgery, percutaneous ablation and liver transplantation are the only curative treatment modality for HCC. However, a majority of patients have unresectable disease at diagnosis. Despite radical treatment, high risk of tumor recurrence is the most common problem. Therefore, there is a need for effective treatment options for patients with advanced or recurrent HCC. For patients with advanced stage of HCC according to the Barcelona Clinic Liver Cancer staging system, the multikinase inhibitor sorafenib is the current standard of care. However, hepatic arterial infusion chemotherapy (HAIC) have been applied to advanced stage HCC with a view to improve the therapeutic indexes in Asia. HAIC provides direct drug delivery into tumor bed and a greater first‐pass effect; also systemic side effects can be potentially minimized. However, the sample size of researches on HAIC was small and large randomized trials are still lacking. In this article, we describe the treatment efficacy of HAIC for advanced stage HCC and discuss future therapeutic possibilities.
Key Words: Hepatocellular carcinoma; Advanced stage HCC; Hepatic arterial infusion chemotherapy


Browse all articles >

Editorial Office
1527 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2019 by The Korean Liver Cancer Association. All rights reserved.

Developed in M2community

Close layer
prev next